Login to Your Account

Jounce bounce: Celgene deal a lure as upsized IPO tops $100M

By Marie Powers
News Editor

Friday, January 27, 2017

Jounce Therapeutics Inc. rose to the head of the pack of early 2017 biopharma IPOs by pricing an upsized offering of 6.365 million shares at $16 apiece, above the intended range of $13 to $15, for proceeds of $101.8 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription